Endometrial cancer is the most common gynecologic malignancy in the US

Icon: 1 out of 4 women

Approximately 1 out of 4 people with endometrial cancer have cancer that has returned or it has spread to other parts of the body (advanced cancer).

The role of dMMR in endometrial cancer

dMMR, or mismatch repair deficiency, is an important biomarker in endometrial cancer

Biomarkers can help diagnose cancer or determine the best treatment option for each patient. Up to 30% of people with endometrial cancers have the dMMR biomarker.

Image: Portrait of woman 1

Knowing whether your endometrial cancer is dMMR can help your doctor choose the right treatment for you.

Your doctor can perform a test that can tell if your endometrial cancer is dMMR. JEMPERLI has been shown to be effective against confirmed dMMR endometrial cancer that has returned or spread (advanced cancer) and after you have received chemotherapy that contains platinum and it did not work or is no longer working, and your cancer cannot be treated by surgery or radiation. If you have questions about dMMR and how JEMPERLI may help you, talk to your doctor today.

Learn more about testing to know your dMMR status: Download Flashcard Now

Icon: Lightbulb

How may JEMPERLI help?

See the Benefits of JEMPERLI

Icon: Gears

How may JEMPERLI fight cancer?

See How JEMPERLI Works